Novartis withdraws EU Tasigna application
This article was originally published in Scrip
Executive Summary
Novartis has withdrawn an application asking the European Medicines Agency to approve Tasigna (nilotinib) in an expanded chronic myeloid leukemia (CML) indication, after the agency's committee indicated it was unlikely to approve the drug based on the data available.